收费全文 | 22849篇 |
免费 | 1699篇 |
国内免费 | 55篇 |
耳鼻咽喉 | 260篇 |
儿科学 | 596篇 |
妇产科学 | 499篇 |
基础医学 | 3083篇 |
口腔科学 | 420篇 |
临床医学 | 2777篇 |
内科学 | 4809篇 |
皮肤病学 | 402篇 |
神经病学 | 2314篇 |
特种医学 | 1072篇 |
外国民族医学 | 2篇 |
外科学 | 3009篇 |
综合类 | 191篇 |
一般理论 | 12篇 |
预防医学 | 1979篇 |
眼科学 | 522篇 |
药学 | 1302篇 |
中国医学 | 30篇 |
肿瘤学 | 1324篇 |
2023年 | 184篇 |
2022年 | 344篇 |
2021年 | 744篇 |
2020年 | 409篇 |
2019年 | 643篇 |
2018年 | 695篇 |
2017年 | 548篇 |
2016年 | 590篇 |
2015年 | 667篇 |
2014年 | 954篇 |
2013年 | 1145篇 |
2012年 | 1795篇 |
2011年 | 1826篇 |
2010年 | 971篇 |
2009年 | 949篇 |
2008年 | 1435篇 |
2007年 | 1434篇 |
2006年 | 1324篇 |
2005年 | 1286篇 |
2004年 | 1223篇 |
2003年 | 1129篇 |
2002年 | 972篇 |
2001年 | 235篇 |
2000年 | 183篇 |
1999年 | 249篇 |
1998年 | 199篇 |
1997年 | 166篇 |
1996年 | 156篇 |
1995年 | 125篇 |
1994年 | 104篇 |
1993年 | 99篇 |
1992年 | 107篇 |
1991年 | 124篇 |
1990年 | 96篇 |
1989年 | 88篇 |
1988年 | 98篇 |
1987年 | 108篇 |
1986年 | 109篇 |
1985年 | 95篇 |
1984年 | 79篇 |
1983年 | 61篇 |
1982年 | 56篇 |
1981年 | 64篇 |
1980年 | 56篇 |
1979年 | 63篇 |
1978年 | 37篇 |
1977年 | 35篇 |
1976年 | 39篇 |
1975年 | 52篇 |
1974年 | 37篇 |
Areas covered: We discuss the current understanding of the HH pathway as it relates to normal hematopoiesis, the pathology of acute myeloid leukemia (AML), the rationale for and data from combination therapies including HH pathway inhibitors, and ultimately the prospects that might offer promise in targeting this pathway in AML.
Expert opinion: Efforts to target the HH pathway have been focused on impeding this disposition and restoring chemosensitivity to conventional myeloid neoplasm therapies. The year 2018 saw the first approval of a HH pathway inhibitor (glasdegib) for AML, though for an older population and in combination with an uncommonly-used therapy. Several other clinical trials with agents targeting modulators of HH signaling in AML and MDS are underway. Further study and understanding of the interplay between the numerous aspects of HH signaling and how it relates to the augmented survival of AML will provide a more reliable substrate for therapeutic strategies in patients with this poor-risk disease. 相似文献
Objective
To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.Methods
This double-blinded, sham-controlled study enrolled 48 subjects and measured headache severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of adjunctive nVNS compared to sham stimulation and suitably matched controls.Results
No significant differences were observed at baseline and after 2 months for headache severity, total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the verum nVNS group and circulating pro-inflammatory IL-1β was elevated significantly in the sham group compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups compared to healthy controls, but not at 2 months follow-up [p?<?0.05]. Concentrations of high-mobility group box-1 (HMGB-1), IL-6, tumor-necrosis factor-α (TNF-α), leptin, adiponectin, ghrelin remained unchanged [p?>?0.05]. No severe device-/stimulation-related adverse events occurred.Conclusion
2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/month. Pro-inflammatory IL-1β plasma levels [inter-ictal] were higher in sham-treated migraine patients compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-α, leptin] and anti-inflammatory [IL-10, adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by pre-analytic variables warranting large-scale biobank-based systematic investigations [omics]. 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献